Geldanamycin CAS:30562-34-6

In kasta oo geldanamycin ay muujisay firfircooni ka-hortagga kansarka daraasadaha shaybaarka, isticmaalkeeda caafimaadku waa xaddidan yahay sababtoo ah caqabadaha la xiriira sunta iyo xasilloonida. Dadaallada cilmi-baarista ayaa socda si loo horumariyo derivatives iyo analogs of geldanamycin oo leh sifooyin pharmacokinetic ah oo la wanaajiyey iyo waxyeellooyin yar oo loogu talagalay codsiyada daaweynta ee suurtagalka ah. Goobaha tijaabada ah, geldanamycin iyo derivatives-keeda ayaa la baaray awooddooda ay ku joojin karaan shaqada Hsp90, taasoo horseedaysa burburka borotiinnada macaamiisha ee ku lug leh koritaanka unugyada kansarka iyo badbaadada. Habkani wuxuu ka dhigayaa geldanamycin musharax rajo leh oo loogu talagalay daaweynta kansarka ee la beegsanayo, gaar ahaan kansarka ku tiirsan waddooyinka ay maamusho Hsp90. Tijaabooyinka kiliinikada ee sahaminta waxtarka iyo badbaadada derivatives geldanamycin ee bukaanada kansarka ayaa socda si loo qiimeeyo awooddooda ah inay yihiin wakiilada ka hortagga kansarka. Daraasadahani waxay higsanayaan inay qiimeeyaan faa'iidooyinka daaweynta daawada, hababka qiyaasta ugu fiican, heerarka jawaabta, iyo waxyeellooyinka kale ee la xiriira si loo go'aamiyo faa'iidadooda caafimaad ee ku jirta dhaqanka kansarka. Iskaashiga u dhexeeya cilmi-baarayaasha, shirkadaha dawooyinka, hay'adaha sharciyeynta, iyo bixiyeyaasha daryeelka caafimaadka ayaa lagama maarmaan u ah horumarinta daaweynta ku salaysan geldanamycin iyo keenista daaweyn cusub oo ka-hortagga kansarka bukaanada u baahan. Baaritaanka joogtada ah ee ku saabsan astaamaha daawada iyo natiijooyinka caafimaad ee ka soo baxa derivatives geldanamycin wuxuu ballan qaadayaa horumarinta istaraatiijiyadaha daaweynta kansarka iyo natiijooyinka mustaqbalka.